

The equine arteritis virus isolate from the 2010 Argentinian outbreak

This paper (No. 22102014-00048-EN) has been peer-reviewed, accepted, edited, and corrected by authors. It has not yet been formatted for printing. It will be published in December 2014 in issue 33-3 of the *Scientific and Technical Review*

G.E. Metz ^(1, 2), M.S. Serena ⁽³⁾, C.J. Panei ^(2, 3), E.O. Nosetto ⁽¹⁾ & M.G. Echeverría ^{(1, 2)*}

(1) Virology, Faculty of Veterinary Sciences, National University of La Plata, 60 and 118, CC 296, 1900 La Plata, Argentina

(2) Members of CONICET-CCT (Consejo Nacional de Investigaciones Científicas y Técnicas – Centro Científico Tecnológico), La Plata, Argentina (Scientific Research Council)

(3) Immunology, Faculty of Veterinary Sciences, National University of La Plata, 60 and 118, CC 296, 1900 La Plata, Argentina

*Corresponding author: gecheverria@fcv.unlp.edu.ar;
mariagabrielaecheverria@yahoo.com.ar

Summary

A semen sample from a stallion infected during the 2010 equine arteritis virus (EAV) outbreak was received for viral isolation prior to castration of the animal. The virus was identified using a polyclonal antibody immunofluorescence test. Reverse-transcription polymerase chain reaction (RT-PCR) was used to amplify a region of the GP5 gene with primers GL105F and GL673R. The PCR products were purified and sequences of both strands were determined in a MegaBACETM 1000 with inner primers CR2 and EAV32. A phylogenetic dataset was built with the previously reported sequences of five strains isolated in Argentina, together with a group of selected sequences obtained from GenBank. The unrooted neighbour-joining tree was constructed using molecular evolutionary genetic analysis (MEGA) and bootstrap analyses were conducted using 1,000 replicate datasets. Evolutionary distances were computed using the maximum

composite likelihood method. A NetNGlyc server analysis at the Technical University of Denmark (www.cbs.dtu.dk/services/NetNGlyc/) was used to predict N-glycosylation in GP5 sequences. The phylogenetic analysis revealed that the new strain (GLD-LP-ARG), together with other strains previously isolated, belongs to the European group EU-1 but in a different branch. The new strain shows 99% nucleotide identity with strain A1 and 98.1% with the Belgian strain 08P178. Persistently infected stallions and their cryopreserved semen constitute a reservoir of EAV, which ensures its persistence in the horse population around the world. These findings reinforce the importance of careful monitoring of persistently infected stallions, as well as semen straws, by RT-PCR or test mating, in accordance with national regulations.

Keywords

Argentina – Equine arteritis virus – Outbreak – Semen sample.

Introduction

Equine arteritis virus (EAV) was first isolated from fetal lung tissue during an outbreak of respiratory disease and abortion in Bucyrus, Ohio, in the United States of America (USA) (1). Until 2010, the prevalence of EAV-infected stallions resident in Argentina was thought to be very low. The first report of serological evidence was in 1984 (2), when a prevalence of 9.2% was found in the population of warmblood horses sampled. The virus (strain LP01) was first isolated in 2001 (3); later, strain LT-LP-ARG was isolated from the testicle of a seropositive stallion that had been imported into Argentina in 1998 (4). In 1998, several EAV antibody-positive animals were detected in two sport-horse breeding farms that practised artificial insemination with imported semen. A follow-up study between July 2001 and December 2003 found a prevalence of 45.8% in one of those farms; three stallions were virus isolation-positive (strains LP02/R, LP02/C, LP02/P) (5). Three new sequences of EAV from three archive semen samples were obtained in 2008: one (RO-LP-ARG) from a stallion housed on the breeding farm where the first strain of EAV was isolated and the other two (RZ-LP-ARG, KB-LP-ARG) from the farm

where the LP02 strains had been isolated (6). Before the 2010 occurrence of equine viral arteritis in Argentina, the virus had not been involved in respiratory disease, abortion or foal death; the prevalence was restricted to sport-horse breeds and to certain breed lineages (7). Phylogenetic investigations of the virus have focused on the hypervariable region of the GP5 gene, in both European and North American strains (8, 9, 10). At present, Argentinian EAV strains all belong to the same group (6, 11, 12). Although infrequently reported in the past, confirmed outbreaks of arteritis appear to be on the increase and in the past decade the disease has been reported in the USA (13), France (14) and Belgium (15). Analysis of phylogenetic relationships has been demonstrated to be an effective tool in tracing the source of EAV infection.

In 2010, two mares on a thoroughbred breeding farm in Buenos Aires Province seroconverted after insemination with frozen semen imported from the Netherlands. The semen straws from the stallion believed to be responsible for spreading the infection were submitted to the Virology Laboratory, National Institute of Agricultural Technology, Castelar, Buenos Aires, and EAV was isolated (16). Four other farms that had used this semen were put into quarantine and all the mares that had been inseminated with the infective semen were found to be seropositive.

A high prevalence of EAV infection was also found at an equestrian club located in central Buenos Aires, where two other mares had been inseminated with infective semen from a stallion housed at the club. Respiratory disease, fever, limb oedema and abortions were observed during this outbreak. Twenty-seven jumping stallions seroconverted and 22 persistently infected stallions were castrated. In the present study, the ORF5 region of this EAV strain was analysed genetically and compared with sequences of other strains from Argentina and elsewhere.

Materials and methods

Sample processing and virological methodology

The infected stallion at the equestrian club in central Buenos Aires was a Hannoverian born in 2000 that had been housed at the club since 2006; the horse was found to be seropositive in May 2010. Before castration of the animal, a semen sample was processed for routine virus isolation at the Virology Laboratory, Faculty of Veterinary Sciences, National University of La Plata, as described previously (3, 17). Briefly, serial tenfold dilutions (10^{-1} to 10^{-3}) of the sample were inoculated in duplicate onto RK13 cells grown in 6-well plates. The cells were maintained in culture medium containing 2% fetal bovine serum. Plates were incubated at 37°C in an atmosphere of 5% CO₂ and examined daily for cytopathic effects. The virus was identified using a polyclonal antibody immunofluorescence test, as described previously (3).

Reverse-transcription polymerase chain reaction and sequencing

Viral RNA was extracted from 500 µl of the supernatant of infected RK13 cells with 500 µl of TRIzol[®] (Invitrogen) and precipitated with isopropanol. Portions (5 µl) of RNA resuspended in distilled water were used for cDNA synthesis using reverse transcriptase and random hexamers (Promega). For PCR amplification, the primers GL105F and GL673R, which flank a 546-nt region of the GP5 gene, were used (18). Denaturation, annealing and extension consisted of 35 cycles at 94°C for 45 s, 60°C for 1 min and 72°C for 90 s, respectively. The PCR products were run on 2% agarose gels, stained with ethidium bromide, observed under UV light and purified using a PCR purification kit. The sequences of both strands were determined in a MegaBACE[™] 1000 with primers CR2 and EAV32, which flank a 519-nt region (8).

Dataset and phylogenetic analysis

The phylogenetic dataset was built with five strains isolated in Argentina, sequences reported previously (3, 4, 5, 6, 11), and a group of selected sequences obtained from GenBank (Table I). Sequences were edited using BioEdit software version 5 (19) and aligned in molecular evolutionary genetic analysis (MEGA) software, version 4.0, using the ClustalW algorithm. Sequence pair distances were calculated by DNASTar[®] (20). The unrooted neighbour-joining tree was constructed using MEGA and bootstrap analyses were conducted using 1,000 replicate datasets. Evolutionary distances were computed using the maximum composite likelihood method (20).

Analysis of N-glycosylation sites

A NetNGlyc server analysis at the Technical University of Denmark (www.cbs.dtu.dk/services/NetNGlyc/) was used to predict N-glycosylation in GP5 sequences. This program predicts asparagines to be N-glycosylated according to the Asn-Xaa-Ser/Thr sequons (where Xaa is not Pro), with a threshold of 0.5.

Results

Viral isolation and reverse-transcription polymerase chain reaction

After two passages in confluent monolayers of RK13 cells, cytopathic effects were observed in cells inoculated with the seminal plasma at 10^{-1} and 10^{-2} dilutions when compared with control cells. The isolated virus strain was named GLD-LP-ARG. After reverse transcription, cDNA was obtained from the supernatants of the cultures. An immunofluorescence test confirmed the presence of EAV antigen; no virus-specific fluorescence was observed in control mock-infected cells. Using primers specific for the GP5 gene, the cDNA gave a visible 591-bp band in an ethidium bromide-stained agarose gel. No bands were observed in the negative control used in the PCR. The 519-bp sequence was analysed and aligned with the Argentinian EAV

isolates and sequences previously reported, and also with American and European reference strains.

Phylogenetic analysis

The partial nucleotide sequence data for gene GP5 reported here have been previously submitted to GenBank under accession number JQ316510. The distance tree obtained by the neighbour-joining algorithm showed that all the Argentinian sequences, except for the first isolate (LP01), are clustered together with high bootstrap values. However, the new isolate, GLD-LP-ARG, is closely related to strains P1, R1, A1, G1, H20, H22, F23 and 08P178, with LP01 as the most basal strain of EAV in the EU-1 subgroup (Fig. 1). Use of other algorithms such as maximum likelihood revealed the same topology: one group comprises the LP02 strains (LP02/R, LP02/C, LP02/P), LT-LP-ARG, RZ-LP-ARG, RO-LP-ARG and KB-LP-ARG; another comprises some European strains and GLD-LP-ARG, with the LP01 strain being the most basal of the group (Fig. 1). The percentage identity among the EAV sequences from the EU-1 clade where the Argentinian strains are located varied between 87.8% and 100%. Strain GLD-LP-ARG shares 99% nucleotide identity with strain A1 and 98.1% with the Belgian strain 08P178.

Analysis of N-glycosylation sites

Changes in GP5 in the Argentinian sequences are described below. The deduced amino acid sequences (51–222) of the variable and conservative regions of the protein are illustrated in Fig. 2. There are no deletions or insertions. In the first constant region (C1), the only substitution that was found had already been reported (position 57 Cys x Trp in strain LP02/R) (12). The second constant region (C2) remained invariable in all the sequences and the third constant region (C3) showed only substitution in KB-LP-ARG (position 199 Ala x Thr). Analysis of the V1 region (amino acids 61–121) showed that Cys in positions 63, 66 and 80 remained invariable in all the Argentinian sequences. As previously reported (12), neutralising site C (amino acids 67–90) was hypervariable. However, one change (position 70 Asp x Ser) was new for sequences in the 2010 outbreak

strain (GLD-LP-ARG). In contrast, Asp x Glu (position 71) appeared in both GLD-LP-ARG and LP01 (the first strain isolated in Argentina), and Glu x Gly (position 93) appeared in KB-LP-ARG. Regarding amino acids 81–84, when analysing the putative N-linked glycosylation sites, all the sequences showed asparagine sites at amino acid 81 (variable) and in position 56 (conserved and critical for virus infectivity). It has been reported that loss of glycosylation sites in other arteriviruses can alter the virulence and tropism of the virus but it is not known whether these changes play an analogous role in EAV (21). However, according to the prediction glycosylation program used here, the asparagines present in position 81 were not sufficient to glycosylate in strains LP01 and LP02/P.

Discussion

Most EAV strains belong to one of three large genetic groups (EAV-1, EAV-2, EAV-3) (18). This classification has been modified recently as a North American clade (NA, formerly EAV-2) and a European clade (EU) with two subgroups (EU-1 and EU-2, formerly EAV-1 and EAV-3 respectively) (21). This approach has also been used to construct the phylogeny of isolates in Poland (22), where 44 isolates are included in the European subgroups (EAV-1 or EAV-3). The new Argentinian strain shares similarity with several European phylogenetic strains such as H20 and H22 (Hungary), F23 (France) and 08P178, the last strain isolated from an outbreak in Belgium, as well as with P1, R1, A1 and G1 isolated in the USA (15). Strain S-113 from the Netherlands belongs to the North American group. To date, none of the Argentinian strains has been linked to the North American EAV strains. Differences are mostly localised in the V1 region, in particular within the neutralisation sites B, C and D. As previously reported, South African donkey isolates were classified in subgroup EU-2 but formed only one cluster (21). Furthermore, six isolates from Lipizzaner stallions in South Africa belonged to subgroup EU-1 and did not cluster with the South African asinine strains, thus representing a unique variant (21). As expected, some sequences, such as H21, SWZ64, S3 and S4, did not form statistically supported

clusters and therefore formed an unclassifiable group of highly variable sequences branching off near the centre.

According to data from the Argentinian authorities, EAV was isolated from the imported semen of a stallion in the Netherlands. Some Argentinian premises were infected as a consequence of using the infective semen or through the movement of infected horses without observation of clinical signs after spread of the virus via the respiratory route. In the present study, a stallion housed in an equestrian club was castrated because it was persistently infected and shedding the virus in semen. The prevalence of infection at the club was very high (80%). The genetic characterisation reported here confirms that the strain from the 2010 Argentinian outbreak belongs to subgroup EU-1, together with all the Argentinian sequences reported to date.

Previously, all Argentinian isolates were related to a non-pathogenic strain and this is the first report of an EAV isolate associated with clinical signs in Argentina. Regarding virulence, EAV strains can be classified as velogenic, mesogenic or lentogenic, according to the clinical signs (23): velogenic strains cause fatal disease in adult horses, mesogenic strains cause less severe disease and lentogenic strains do not cause any clinical signs. Loss of virulence in EAV has been related to the amino acids sequences of structural and nonstructural proteins, and eight critical amino acid substitutions in the structural protein GP5 have been identified as being responsible for EAV attenuation (23). The same amino acid substitutions were observed in the present study when comparing velogenic and mesogenic strains (23). Although the amino acid substitutions of the 2010 EAV Argentinian isolate related to a high- or medium-virulence strain, analysis of strain virulence is more complex; GP5 analysis alone provides an approximation, but analysis of other structural and nonstructural proteins is required. Further, host genetic factors such as the haplotype of the equine could determine resistance or susceptibility to EAV infection and thus influence the capability of the virus to generate clinical signs (24).

In summary, the EAV-infected equine population in Argentina in 2010 showed mild clinical signs that could be correlated by analysing the sequence of gene GP5. Using amino acid substitution, the 2010 isolate was grouped with velogenic or mesogenic strains (23). According to the phylogenetic study, this strain has high similarity with the Belgian strain 08P178, also reported as a European subtype of low virulence (25). The Belgian strain was used recently in an experimental infection in naïve ponies (26) where it produced mild clinical signs when compared with North American strains (27). It was concluded that the differences in clinical signs may be dependent on both the viral strain and the breed of animal (26).

Stallions and their cryopreserved semen constitute a reservoir of EAV, thus ensuring persistence of the virus in the horse population around the world and causing new outbreaks such as that in Argentina in 2010. These findings reinforce the importance of careful monitoring of EAV in persistently infected stallions, as well as in semen straws, by RT-PCR or test mating, according to national regulations. Although most EAV strains are of low virulence, outbreaks with severe clinical signs may occur.

Conclusion

The new Argentinian strain shows 99% nucleotide identity with strain A1 and 98.1% with the Belgian strain 08P178.

Acknowledgements

The assistance of Ms A. Conde and Mr C. Leguizamon is very gratefully acknowledged.

References

1. Doll E.R., Bryans J.T., McCollum W.H. & Crowe M.E.W. (1957). – Isolation of a filterable agent causing arteritis of horses and abortion in mares; its differentiation from the equine abortion (influenza) virus. *Cornell Vet.*, **47** (1), 3–41.

2. Nosetto E.O., Etcheverrigaray M.E., Oliva G.A., González E.T. & Samus S.A. (1984). – Equine viral arteritis: detection of antibodies of horses in Argentina. *Zentralbl. Veterinärmed., B*, **31** (7), 526–529.

3. Echeverría M.G., Pecoraro M.R., Galosi C.M., Etcheverrigaray M.E. & Nosetto E.O. (2003). – The first isolation of equine arteritis virus in Argentina. *Rev. sci. tech. Off. int. Epiz.*, **22** (3), 1029–1033.

4. Metz G.E., Serena M.S., Ocampos G.M., Panei C.J., Fernández V.L. & Echeverría M.G. (2008). – Equine arteritis virus: a new isolate from the presumable first carrier stallion in Argentina and its genetic relationships among the four reported unique strains. *Arch. Virol.*, **153** (11), 2111–2115.

5. Echeverría M.G., Díaz S., Metz G.E., Serena M.S., Panei C.J. & Nosetto E.O. (2007). – Genetic typing of equine arteritis virus isolates from Argentina. *Virus Genes*, **35** (2), 313–320.

6. Metz G.E., Serena M.S., Díaz S. & Echeverría M.G. (2008). – Caracterización de secuencias del virus de la arteritis equina obtenidas directamente de muestras de semen de equinos seropositivos. *Analecta Veterinaria*, **28** (2), 21–26.

7. Vissani A., Iglesias M., Echeverría M.G., Tordoya S., La Torre J., Metz G., Becerra L., Serena S., Olguin Perglione C. & Barrandeguy M. (2008). – Equine viral arteritis: current status in Argentina. Second International Workshop on Equine Viral Arteritis 13–15 October 2008, Lexington, Kentucky.

8. Stadejek T., Bjorklund H., Ros Bascunana C., Ciabatti I.M., Scicluna M.T., Amaddeo D., McCollum W.H., Autorino G.L., Timoney P.J., Paton D.J., Klingeborn B. & Belak S. (1999). – Genetic diversity of equine arteritis virus. *J. Gen. Virol.*, **80** (3), 691–699.

9. Larsen L.E., Storgaard T. & Holm E. (2001). – Phylogenetic characterization of the GL sequences of equine arteritis virus isolated

from semen of asymptomatic stallions and fatal cases of equine viral arteritis in Denmark. *Vet. Microbiol.*, **80** (4), 339–346.

10. Hornyak A., Bakonyi T., Tekes G., Szeredi L. & Rusvai M. (2005). – A novel subgroup among genotypes of equine arteritis virus: genetic comparison of 40 strains. *J. vet. med. Sci. B*, **52** (3), 1–7.

11. Metz G.E., Ocampos G.P., Serena M.S., Gambaro S.E., Nosetto E. & Echeverría M.G. (2011). – Extended phylogeny of the equine arteritis virus sequences including South American sequences. *Intervirology*, **54** (1), 30–36.

12. Echeverría M.G., Díaz S., Metz G.E., Serena M.S., Panei C.J. & Nosetto E. (2010). – Evaluation of neutralization patterns of the five unique Argentine equine arteritis virus field strains reported. *Rev. argent. Microbiol.*, **42** (1), 11–17.

13. Zhang J., Timoney P., Shuck K., Seoul G., Go Y., Lu Z., Powell D.G., Meade B.J. & Balasuriya U.B. (2010). – Molecular epidemiology and genetic characterization of equine arteritis virus isolates associated with the 2006–2007 multi-state disease occurrence in the USA. *J. gen. Virol.*, **91** (9), 2286–2301.

14. Pronost S., Pitel P.H., Miszczak F., Legrand L., Marcillaud-Pitel C., Hamon M., Tapprest J., Balasuriya U.B., Freymuth F. & Fortier G. (2010). – Description of the first recorded major occurrence of equine viral arteritis in France. *Equine vet. J.*, **42** (8), 713–720.

15. Gryspeerdt A., Chiers K., Govaere J., Vercauteren G., Ducatelle R., Van de Walle G.R. & Nauwynck H.J. (2009). – Neonatal foal death due to infection with equine arteritis virus in Belgium. *Vlaams diergeneesk. Tijdschr.*, **78**, 189–193.

16. Olguin Perglione C., Córdoba M., Echeverría M.G., Timoney P., Tordoya S., Darqui F., Metz G.E., Miño S., Becerra L., Serena M.S., Vissani A., González E.T., Silvestrini M.P., Corva S., Uncal L., Dayraut J., Badaracco A. & Barrandeguy M. (2010). – Equine viral arteritis outbreak in Argentina. *In Proc. 114th Annual*

Meeting of the United States Animal Health Association, 12–16 November, Minneapolis, Minnesota.

17. Timoney P.J., McCollum W.H. & Roberts A.W. (1987). – Detection of the carrier state in stallions persistently infected with equine arteritis virus. *Proc. Am. Assoc. Equine Pract*, **32**, 57–65.

18. Mittelholzer C., Stadejek T., Johansson I., Baule C., Ciabatti I., Hannant D., Paton D., Autorino G.L., Nowotny N. & Belak S. (2006). – Extended phylogeny of equine arteritis virus: division into new subgroups. *J. vet. Med., B*, **53** (2), 55–58.

19. Hall T.A. (1999). – BioEdit: a user friendly biological sequences alignment editor and analysis program for Windows 95/98/NT. *Nucl. Acids Symp. Ser.*, **41**, 95–98.

20. Tamura K., Dudley J., Nei M. & Kumar S. (2007). – MEGA4: molecular evolutionary genetic analysis (MEGA) software version 4.0. *Molec. Biol. Evol.*, **24** (8), 1596–1599.

21. Zhang J., Miszczak F., Pronost S., Fortier C., Balasuriya U.B., Zientara S., Fortier G. & Timoney P.J. (2007). – Genetic variation and phylogenetic analysis of 22 French isolates of equine arteritis virus. *Arch. Virol.*, **152** (11), 1977–1994.

22. Larska M. & Rola J. (2008). – Molecular epizootiology of equine arteritis virus isolates from Poland. *Vet. Microbiol.*, **127** (3–4), 392–398.

23. Zhang J., Go Y.Y., MacLachlan N.J., Meade B.J., Timoney P.J. & Balasuriya U.B.R. (2008). – Amino acid substitutions in the structural or nonstructural proteins of a vaccine strain of equine arteritis virus are associated with its attenuation. *Virology*, **378** (2), 355–362.

24. Balasuriya U.B.R., Go Y.Y. & MacLachlan N.J. (2013). – Equine arteritis virus. *Vet. Microbiol.*, **167** (1–2), 93–122.

25. Vairo S., Vandekerckhove A., Steukers L., Glorieux S., Van den Broeck W. & Nauwynck H. (2012). – Clinical and virological outcome of an infection with the Belgian equine arteritis virus strain 08P178. *Vet. Microbiol.*, **157** (3–4), 333–344.

26. Vairo S., Saey V., Bombardi C., Ducatelle R. & Nauwynck H. (2014). – The recent European isolate (08P178) of equine arteritis virus causes inflammation but not arteritis in experimentally infected ponies. *J. comp. Pathol.* doi:10.1016/j.jcpa.2014.04.008.


27. Del Piero F. (2000). – Equine viral arteritis. *Vet. Pathol.*, **37** (4), 287–296.

Table I
Origins, names and phylogenetic groups of the equine arteritis virus strains used in this study

Virus strain	Country of isolation	GenBank accession no.	Phylogenetic group
F5	France	EF492543	NA
F6	France	EF492544	NA
F7	France	EF492545	NA
F8	France	EF492546	NA
F9	France	EF492547	EU-1
F10	France	EF492548	EU-2
F11	France	EF492549	NA
F12	France	EF492550	NA
F13	France	EF492551	NA
F14	France	EF492552	NA
F15	France	EF492553	EU-2
F23	France	EF492561	EU-1
F24	France	EF492562	NA
F25	France	EF492563	NA
F26	France	EF492564	NA
H20	Hungary	AY453305	EU-1
H21	Hungary	AY453306	EU-1
H22	Hungary	AY453307	EU-1
H23	Hungary	AY453308	EU-1
H24	Hungary	AY453309	EU-2
I13	Italy	AY453310	EU-1
I14	Italy	AY453311	NA
I15	Italy	AY453312	NA
I16	Italy	AY453313	EU-1
I17	Italy	AY453314	EU-1
I18	Italy	AY453315	EU-1
I19	Italy	AY453316	NA
I20	Italy	AY453317	EU-1
PLA00-1	Poland	EF102348	EU-1
PLB01-1	Poland	EF102349	EU-1
PLG02-1	Poland	EF102354	EU-1
PLK02-8	Poland	EF102363	EU-1
PLH05-1	Poland	EF102355	EU-1
J25-941109-3	South Africa	AY956603	EU-2
J7-931125	South Africa	AY956602	EU-2
J6-940309	South Africa	AY956601	EU-2

J5-940309	South Africa	AY956600	EU-2
J4-931209	South Africa	AY956599	EU-2
J3-931209	South Africa	AY956598	EU-2
J2-931125	South Africa	AY956597	EU-2
J1-931125	South Africa	AY956596	EU-2
RSA1	South Africa	AY453332	EU-2
RSA2	South Africa	AY453333	NA
RSA3	South Africa	AY453334	EU-1
RSA4	South Africa	AY453335	EU-1
RSA5	South Africa	AY453336	EU-1
RSA6	South Africa	AY453337	EU-1
RSA7	South Africa	AY453338	EU-1
RSA8	South Africa	AY453339	EU-1
S2	Sweden	AY453340	EU-2
S3	Sweden	AY453341	EU
S4	Sweden	AY453342	EU
S5	Sweden	AY453343	EU-2
S6	Sweden	AY453344	EU-2
S7	Sweden	AY453345	EU-2
S-113	Holland	AF099833	NA
S-544	New Zealand	AF099834	NA
SWZ64	Switzerland	U38609	EU
KY84	USA	AF107279	NA
KY93	USA	U81017	NA
VBS53	USA	U81013	NA
D84	USA	AF107266	NA
E85	USA	AF107275	NA
G1	USA	AF118777	EU-1
P1	USA	AF118775	EU-1
R1	USA	AF118773	EU-1
A1	USA	AF118769	EU-1
MT89	USA	U38604	NA
08P178	Belgium	JN254761	EU-1
LP01	Argentina	DQ435439	EU-1
LP02/R	Argentina	DQ435440	EU-1
LP02/C	Argentina	DQ435441	EU-1
LP02/P	Argentina	DQ435442	EU-1
LT-LP-ARG	Argentina	EU622859	EU-1
KB-LP-ARG	Argentina	EU622860	EU-1
RZ-LP-ARG	Argentina	EU622861	EU-1
RO-LP-ARG	Argentina	EU622862	EU-1
GLD-LP-ARG	Argentina	JQ316510	EU-1

Fig. 1
Maximum likelihood phylogenetic tree based on analysis of ORF5 nucleotide sequences in equine arteritis virus strains
Bootstrapping of the tree was carried out in 1,000 duplicates using the MEGA 4.0 software program






Fig. 2

Alignment of deduced amino acids for partial GP5 sequences in Argentinian equine arteritis virus strains

Non-consensus amino acids are in bold letters. Variable and conserved regions are indicated with capital letters. Neutralisation sites B, C and D are indicated in boxes. Predicted N-glycosylation sites are underlined

		Neut. Site B	Neut. Site C	Neut. Site D			
		c1	v1		c2		
RO-LP-ARG	51	HTALY <u>NCSAS</u>	KTCWYCEFLDDQIIITFGTGCNDTYSVPVSTVLEQA <u>H</u> GPYSVLFDDMPPFIYYGREFGIFVM	DVFMFYVPLVLFFLSVLPY			
KB-LP-ARG		HTALY <u>NCSAS</u>	KTCWYCEFLDDQIIITFGTGCNDTYSVPVSTVLEQA <u>H</u> GPYSVLFDDMPPFIYYGREFGIFVM	DVFMFYVPLVLFFLSVLPY			
LT-LP-ARG		HTALY <u>NCSAS</u>	KTCWYCEFLDDQIIITFGTGCNDTYSVPVSTVLEQA <u>H</u> GPYSVLFDDMPPFIYYGREFGIFVM	DVFMFYVPLVLFFLSVLPY			
LP02/R		HTALY <u>NCSAS</u>	KTCWYCEFLDDQIIITFGTGCNDTYSVPVSTVLEQA <u>H</u> GPYSVLFDDMPPFIYYGREFGIFVM	DVFMFYVPLVLFFLSVLPY			
RZ-LP-ARG		HTALY <u>NCSAS</u>	KTCWYCEFLDDQIIITFGTGC <u>N</u> DTYSVPVSTVLEQA <u>H</u> GPYSVLFDDMPPFIYYGREFGIFVM	DVFMFYVPLVLFFLSVLPY			
LP02/C		HTALY <u>NCSAS</u>	KTCWYCVFLDDQIIITFGTGCNDT <u>H</u> SVPVSTVLEQA <u>H</u> GPYSVLFDDMPPFIYYGREFGIFVM	DVFMFYVPLVLFFLSVLPY			
LP02/P		HTALY <u>NCSAS</u>	KTCWYCEFLDDQIIITFGTGC <u>N</u> DTYSVPVSTVLEQA <u>H</u> GPYSVLFDDMPPFIYYGREFGIFVM	DVFMFYVPLVLFFLSVLPY			
GLD-LP-ARG		HTALY <u>NCSAS</u>	KTCWYCEFL <u>SE</u> QIIITFGTGCNDTYSVPVSTVLEQA <u>H</u> GPYSVLFDDMPPFIYYGREFGIFVM	DVFMFYVPLVLFFLSVLPY			
LP01		HTALY <u>NCSAS</u>	E TWCWYCVFLD <u>EQ</u> VITFGTGC <u>N</u> DTYSVPVSTVLEQA <u>H</u> GPYSVLFDDMPPFIYYGREFGIFVM	DVFMFYVPLVLFFLSVLPY			
		*****	*** :***** ** .:***** .:***** *****	*****	*****		
			v2	c3	v3		
RO-LP-ARG		ATLILEMCVSI	ILFVVYGLYSGAYLAMGIFATTLVVHVS	VVLRQLLWLC	LAWRYRCTLHASF	ISAEGKIYPVDPGLPIAAAGN	222
KB-LP-ARG		ATLILEMCVSI	ILFVVYGLYSGAYLAMGIFATTLVVHVS	VVLRQLLWLC	LAWRYRCTLH <u>TS</u> F	ISAERKIYPVDPGLPIAAAGN	222
LT-LP-ARG		ATLILEMCVSI	ILFVVYGLYSGAYLAMGIFATTLVVHVS	VVLRQLLWLC	LAWRYRCTLHASF	ISAEGKIYPVDPGLPIAAAGN	222
LP02/R		ATLILEMCVSI	ILFVVYGLYSGAYLAMGIFATTLVVHVS	VVLRQLLWLC	LAWRYRCTLHASF	ISAEGKIYPVDPGLPIAAAGN	222
RZ-LP-ARG		ATLILEMCVSI	ILFVVYGLYSGAYLAMGIFATTLVVHVS	VVLRQLLWLC	LAWRYRCTLHASF	ISAEGKIYPVDPGLPIAAAGN	222
LP02/C		ATLILEMCVSI	ILFVVYGLYSGAYLAMGIFATTLVVHVS	VVLRQLLWLC	LAWRYRCTLHASF	ISAEGKIYPVDPGLPIAAAGN	222
LP02/P		ATLILEMCVSI	ILFVVYGLYSGAYLAMGIFATTLVVHVS	VVLRQLLWLC	LAWRYRCTLHASF	ISAEGKIYPVDPGLPIAAAGN	222
GLD-LP-ARG		ATLILEMCVSI	ILFVVYGLYSGAYLAMGIFATTLVVHVS	VVLRQLLWLC	LAWRYRCTLHASF	ISAEGKIYPVDPGLPIAAAGN	222
LP01		V TLILEMCVSI	ILFVVYGLYSGAYLAMGIFATTLVVHVS	VVLRQLLWLC	LAWRYRCTLHASF	ISAEGKIYPVDPGLPIAAAGN	222
		.	*****	*****	*****	*****	*****